Inference and Decision Making for 21st-Century Drug Development and Approval
From MaRDI portal
Publication:5868274
DOI10.1080/00031305.2019.1566091OpenAlexW2924924152MaRDI QIDQ5868274
Lisa M. Lavange, Carl Peck, Margaret Gamalo-Siebers, Frank E. jun. Harrell, Unnamed Author, Stephen J. Ruberg, Karen L. Price
Publication date: 20 September 2022
Published in: The American Statistician (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/00031305.2019.1566091
Bayesian statisticsstatistical inference\(p\)-valueclinical trialprior and posterior probabilitysubstantial evidence
Related Items
Toward Replicability With Confidence Intervals for the Exceedance Probability ⋮ P-values don’t measure evidence ⋮ New Bayesian approaches to equivalence testing ⋮ Moving to a World Beyond “p < 0.05”
Cites Work
- The interplay of Bayesian and frequentist analysis
- Robust Bayesian analysis: sensitivity to the prior
- Bayesian designs and the control of frequentist characteristics: A practical solution
- Determining the Effective Sample Size of a Parametric Prior
- Clinical trial design as a decision problem
- Uncertain Judgements: Eliciting Experts' Probabilities
